Pyxis Oncology Statistics

Total Valuation

Pyxis Oncology has a market cap or net worth of $71.24 million. The enterprise value is -$37.97 million.

Market Cap	71.24M
Enterprise Value	-37.97M

Important Dates

The next estimated earnings date is Tuesday, May 20, 2025, before market open.

Earnings Date	May 20, 2025
Ex-Dividend Date	n/a

Share Statistics

Pyxis Oncology has 61.95 million shares outstanding. The number of shares has increased by 46.46% in one year.

Current Share Class	61.95M
Shares Outstanding	61.95M
Shares Change (YoY)	+46.46%
Shares Change (QoQ)	+0.88%
Owned by Insiders (%)	6.29%
Owned by Institutions (%)	33.25%
Float	44.65M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	3.87
Forward PS	n/a
PB Ratio	0.53
P/TBV Ratio	0.58
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 7.49, with a Debt / Equity ratio of 0.17.

Current Ratio	7.49
Quick Ratio	7.18
Debt / Equity	0.17
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -62.75% and return on invested capital (ROIC) is -28.46%.

Return on Equity (ROE)	-62.75%
Return on Assets (ROA)	-24.77%
Return on Invested Capital (ROIC)	-28.46%
Return on Capital Employed (ROCE)	-47.00%
Revenue Per Employee	$366,955
Profits Per Employee	-$1.76M
Employee Count	44
Asset Turnover	0.10
Inventory Turnover	n/a

Taxes

Income Tax	-2.16M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -73.50% in the last 52 weeks. The beta is 1.15, so Pyxis Oncology's price volatility has been higher than the market average.

Beta (5Y)	1.15
52-Week Price Change	-73.50%
50-Day Moving Average	1.06
200-Day Moving Average	2.32
Relative Strength Index (RSI)	55.67
Average Volume (20 Days)	539,357

Short Selling Information

The latest short interest is 7.23 million, so 11.68% of the outstanding shares have been sold short.

Short Interest	7.23M
Short Previous Month	7.13M
Short % of Shares Out	11.68%
Short % of Float	16.20%
Short Ratio (days to cover)	13.60

Income Statement

In the last 12 months, Pyxis Oncology had revenue of $16.15 million and -$77.33 million in losses. Loss per share was -$1.32.

Revenue	16.15M
Gross Profit	15.67M
Operating Income	-65.57M
Pretax Income	-57.80M
Net Income	-77.33M
EBITDA	-62.59M
EBIT	-65.57M
Loss Per Share	-$1.32

Full Income Statement

Balance Sheet

The company has $126.93 million in cash and $20.20 million in debt, giving a net cash position of $106.73 million or $1.72 per share.

Cash & Cash Equivalents	126.93M
Total Debt	20.20M
Net Cash	106.73M
Net Cash Per Share	$1.72
Equity (Book Value)	120.75M
Book Value Per Share	2.01
Working Capital	114.76M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$57.67 million and capital expenditures -$237,000, giving a free cash flow of -$57.91 million.

Operating Cash Flow	-57.67M
Capital Expenditures	-237,000
Free Cash Flow	-57.91M
FCF Per Share	-$0.93

Full Cash Flow Statement

Margins

Gross Margin	97.06%
Operating Margin	-406.11%
Pretax Margin	-492.35%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Pyxis Oncology does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-46.46%
Shareholder Yield	-46.46%
Earnings Yield	-112.46%
FCF Yield	-84.22%

Analyst Forecast

The average price target for Pyxis Oncology is $9.20, which is 700.00% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$9.20
Price Target Difference	700.00%
Analyst Consensus	Strong Buy
Analyst Count	6
Revenue Growth Forecast (5Y)	40.82%
EPS Growth Forecast (5Y)	-3.11%

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Pyxis Oncology has an Altman Z-Score of -0.27 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.27
Piotroski F-Score	2